Access
To read this story in full you will need to login or make a payment (see right).
News
Nature 440, 855-856 (13 April 2006) | doi:10.1038/440855a; Published online 12 April 2006
Open Innovation Challenges
-
Methods of Modeling Adaptation in Populations
The analysis of adaptation with a population is a frequently encountered computational modeling scen...
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
- More Challenges
- Powered by:
nature jobs
Molecular Biologists and Biochemists
- University of Minnesota
- Minnesota, USA
Admission for Research Scholars Program
- CDFD (Centre for DNA Fingerprinting and Diagnostics)
- Hyderabad, A.P. 500 001 India
Can super-antibody drugs be tamed?
Abstract
As it becomes clear that the London clinical trial disaster was indeed the fault of the drug itself, Michael Hopkin looks at what went wrong, and whether there is any future for 'superagonist' antibody therapies.
There was no warning from animal tests, but last month the experimental antibody drug TGN1412 put six British men in intensive care. The resulting investigation ruled out any failure of experimental and regulatory procedures — a relief for those involved, but a damaging blow for the field.
To read this story in full you will need to login or make a payment (see right).
